
India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears
Dr Reddy’s Laboratories logged its steepest weekly loss in three years on Friday, after a disruption in generic semaglutide supply raised concerns it could lose its edge in the highly competitive diabetes market.



















































































_20260909054021554_9b5681.webp)

